Valuation Novartis AG Mexican S.E.

Stocks

End-of-day quote Mexican S.E. Other stock markets 31/07/2026			5-day change	1st Jan Change
2,710.00 ^MXN	-0.88%		+1.46%	+8.40%

02/08	Novartis' Pluvicto Gets US FDA Nod for Metastatic Prostate Cancer Treatment	MT
01/08	Novartis Wins FDA Approval for Expanded Prostate Cancer Treatment For Pluvicto	DJ

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Market Cap ¹	1,96,458	1,94,448	2,07,167	1,95,514	2,66,003	2,97,394	-	-
Change	-	-1.02%	6.54%	-5.62%	36.05%	11.8%	-	-
Enterprise Value (EV) ¹	2,04,649	2,03,482	2,19,178	2,13,458	2,89,870	3,30,508	3,25,211	3,18,274
Change	-	-0.57%	7.71%	-2.61%	35.8%	14.02%	-1.6%	-2.13%
P/E	8.2x	28.3x	14.1x	16.5x	19.2x	22.2x	19x	16.5x
PBR	2.9x	3.23x	4.41x	4.52x	5.73x	6.26x	5.83x	5.24x
PEG	-	-0.4x	0x	-1x	0.9x	-9.68x	1.1x	1.1x
Capitalization / Revenue	3.81x	3.85x	4.44x	3.78x	4.69x	5.16x	4.87x	4.58x
EV / Revenue	3.96x	4.03x	4.7x	4.13x	5.11x	5.74x	5.32x	4.9x
EV / EBITDA	11.2x	10.9x	12.2x	10.2x	12.4x	14.3x	13x	11.7x
EV / EBIT	12.3x	12.2x	13.4x	10.9x	13.2x	15.2x	13.8x	12.4x
EV / FCF	15.4x	17x	16.6x	13.1x	16.5x	22.8x	20.1x	16.9x
FCF Yield	6.49%	5.87%	6.01%	7.61%	6.07%	4.38%	4.96%	5.93%
Dividend per Share ²	3.36	3.5	3.823	3.856	-	4.376	4.564	4.749
Rate of return	3.83%	3.87%	3.79%	3.94%	-	2.8%	2.92%	3.04%
EPS ²	10.71	3.19	7.15	5.92	7.21	7.045	8.252	9.485
Distribution rate	31.4%	110%	53.5%	65.1%	-	62.1%	55.3%	50.1%
Net sales ¹	51,626	50,545	46,660	51,722	56,674	57,584	61,123	64,991
EBITDA ¹	18,246	18,613	17,937	21,006	23,415	23,083	25,093	27,161
EBIT ¹	16,588	16,665	16,372	19,494	21,889	21,778	23,631	25,619
Net income ¹	24,021	6,955	14,854	11,939	13,967	13,780	15,358	17,285
Net Debt ¹	8,191	9,034	12,011	17,944	23,867	33,114	27,817	20,880
Reference price ²	87.82	90.40	100.79	97.79	138.63	156.46	156.46	156.46
Nbr of stocks (in thousands)	22,37,092	21,50,980	20,55,460	19,99,270	19,18,792	19,00,715	-	-
Announcement Date	02/02/22	01/02/23	31/01/24	31/01/25	04/02/26	-	-	-

¹USD in Million²USD

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
ELI LILLY AND COMPANY	35.03x	12.19x	25.61x	0.59%	1,02400Cr
JOHNSON & JOHNSON	27.48x	6.29x	17.54x	2.1%	62TCr
ABBVIE INC.	32.57x	7.42x	15.35x	2.76%	44TCr
ROCHE HOLDING AG	19.7x	4.68x	11.59x	2.83%	35TCr
ASTRAZENECA PLC	21.76x	4.48x	12.7x	1.96%	26TCr
NOVO NORDISK A/S	13.48x	5.05x	10.4x	3.71%	21TCr
AMGEN INC.	25.29x	6.61x	11.66x	2.62%	21TCr
GILEAD SCIENCES, INC.	-46.92x	5.63x	31.08x	2.53%	16TCr
PFIZER INC.	12.69x	3.11x	7.86x	6.88%	14TCr
Average	15.68x	6.16x	15.98x	2.89%	37.99TCr
Weighted average by Cap.	24.04x	7.68x	18.14x	2.14%